Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor
This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
1. A method of treating cancer in a subject, the method comprising administering to said subject a therapeutically effective amount of a crystalline form of N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N′-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]-urea, wherein said crystalline form is characterized by an x-ray powder diffraction pattern comprising a peak at a 2-theta value of about 4.8±0.2 degrees, and said cancer is selected from melanoma, colorectal cancer, and non-small cell lung cancer.
2. The method according to claim 1 , wherein said cancer is non-small cell lung cancer.
3. The method according to claim 1 , wherein said x-ray powder diffraction pattern further comprises a peak at a 2-theta value of about 14.4±0.2 degrees.
4. The method according to claim 3 , wherein said x-ray powder diffraction pattern further comprises a peak at a 2-theta value of about 14.3±0.2 degrees.
5. The method according to claim 4 , wherein said x-ray powder diffraction pattern further comprises a peak at a 2-theta value of about 14.7±0.2 degrees.
6. The method according to claim 1 , wherein said crystalline form is further characterized by exhibiting a peak in a differential scanning calorimetry scan of about 214° C.
7. The method according to claim 1 , wherein said crystalline form is further characterized by exhibiting a moisture uptake of less than about 1.3% by weight in conditions of relative humidity from about 40% to about 90%.
8. The method according to claim 1 , wherein said crystalline form is further characterized by exhibiting Fourier transform infrared spectrum bands at frequencies of about 3359.1 cm −1 , about 1733.3 cm −1 , about 1607.3 cm −1 , and about 1414.8 cm −1 .
9. A method of treating cancer in a subject, the method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N′-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]-urea and a pharmaceutically acceptable excipient, wherein said crystalline form is characterized by an x-ray powder diffraction pattern comprising a peak at a 2-theta value of about 4.8±0.2 degrees, and said cancer is selected from melanoma, colorectal cancer, and non-small cell lung cancer.
10. The method according to claim 9 , wherein said cancer is non-small cell lung cancer.
11. The method according to claim 9 , wherein said x-ray powder diffraction pattern further comprises a peak at a 2-theta value of about 14.4±0.2 degrees.
12. The method according to claim 11 , wherein said x-ray powder diffraction pattern further comprises a peak at a 2-theta value of about 14.3±0.2 degrees.
13. The method according to claim 11 , wherein said x-ray powder diffraction pattern further comprises a peak at a 2-theta value of about 14.7±0.2 degrees.
14. The method according to claim 9 , wherein said crystalline form is further characterized by exhibiting a peak in a differential scanning calorimetry scan of about 214° C.
15. The method according to claim 9 , wherein said crystalline form is further characterized by exhibiting a moisture uptake of less than about 1.3% by weight in conditions of relative humidity from about 40% to about 90%.
16. The method according to claim 9 , wherein said crystalline form is further characterized by exhibiting Fourier transform infrared spectrum bands at frequencies of about 3359.1 cm−1, about 1733.3 cm −1 , about 1607.3 cm −1 , and about 1414.8 cm −1 .
17. The method according to claim 1 , wherein said cancer is melanoma.
18. The method according to claim 1 , wherein said cancer is colorectal cancer.
19. The method according to claim 9 , wherein said cancer is melanoma.
20. The method according to claim 9 , wherein said cancer is colorectal cancer.